|Over a week ago|
Lannett raises FY20 adj. revenue view to $530M-$550M from $525M-$545M 16:2102/0502/05/20
FY20 consensus $536.21M.
Lannett reports Q2 adjusted EPS 27c, consensus 27c » 16:2002/0502/05/20
Reports Q2 revenue…
Reports Q2 revenue $136.1M, consensus $128.6M.
|Over a month ago|
Fly Intel: Pre-market Movers » 09:2001/1301/13/20
LULU, LCI, WCC, AXE, TERP, BEP, HOME, JILL, ABMD, EXAS, CHKP
HIGHER: Lululemon (LULU),…
HIGHER: Lululemon (LULU), up 2% after raising its Q4 EPS outlook... Lannett (LCI), up 7% after announcing FDA approval of its Cocaine Hydrochloride Nasal Solution new drug application... Wesco (WCC), up 3% after announcing a definitive merger agreement under which the company will acquire Anixter (AXE) in a transaction valued at approximately $4.5B... TerraForm Power (TERP), up 9% after announcing Brookfield Renewable Partners (BEP) has made a non-binding, all-share proposal to acquire the outstanding Class A common shares of the company, other than the 62% owned by Brookfield Renewable and its affiliates... At Home Group (HOME), up 13% after announcing Q4 sales will be at the higher end of the previously guided range... J.Jill (JILL), up 18% after raising its Q4 EPS view. LOWER: Abiomed (ABMD), down 11% after reporting preliminary Q3 revenue... Exact sciences (EXAS), down 6% after reporting preliminary Q4 revenue .. Check Point (CHKP), down 2% after Morgan Stanley analyst Keith Weiss downgraded shares to Underweight from Equal Weight with a price target of $106, down from $115.
Lannett announces FDA approval of its Cocaine Hydrochloride Nasal Solution NDA » 06:5701/1301/13/20
Lannett announced that…
Lannett announced that the FDA has approved the new drug application, or NDA, submitted under the 505 regulatory pathway, for Cocaine Hydrochloride, or HCl, Nasal Solution 4%, the company's branded local anesthetic product. Numbrino nasal solution is an ester local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults. The 505 NDA submission was supported by two Phase III, randomized, double-blind, placebo-controlled, multicenter studies in several hundred patients, as well as a Phase I pharmacokinetic study.
Lannett commences marketing for Venlafaxine ER tablets, Lidocaine solution » 06:5401/0601/06/20
Lannett announced that it…
Lannett announced that it has commenced marketing Venlafaxine extended release, or ER, tablets, 150 mg and 225 mg, USP, and Lidocaine topical solution 4%. The estimated IQVIA market values of Venlafaxine ER tablets, 150 mg and 225 mg, USP, and Lidocaine topical solution 4% are approximately $150M and $17M, respectively, for the 12 months ending November 2019, although actual generic market values are expected to be lower.
Lannett receives FDA approvals for 2 dosage strengths of BAC Capsules » 06:5312/2312/23/19
Lannett announced that it…
Lannett announced that it has received approvals from the FDA of its Abbreviated New Drug Applications, or ANDAs, for Butalbital, Acetaminophen and Caffeine, or BAC, Capsules, USP, 50mg/300mg/40mg and BAC Capsules, USP, 50 mg/325 mg/40 mg. The two dosage strengths of BAC Capsules, have a combined estimated IQVIA market value of approximately $68.6 million for the 12 months ending October 2019, although actual generic market values are expected to be lower.
Lannett files $50M mixed securities shelf 16:1412/2012/20/19
Lannett to commence marketing for generic Adderall XR in coming months » 07:0212/1212/12/19
Lannett announced that it…
Lannett announced that it expects to commence marketing in the coming months a generic version of Adderall XR, an extended-release mixed salt of a single entity Amphetamine tablet product with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg tablets. Adderall XR including generic versions have an estimated IQVIA market value of approximately $1.3B for the 12 months ending October, although actual generic market values are expected to be lower. In March, Lannett entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of certain drug products, including generic Adderall IR and generic Adderall XR. Under the agreement, Lannett primarily provides sales, marketing and distribution support for the products, for which it receives a share of the profits.
Lannett rises 8.3% » 09:4712/0412/04/19
Lannett is up 8.3%, or…
Lannett is up 8.3%, or 74c to $9.60.
Fly Intel: Pre-market Movers » 09:0312/0412/04/19
GPRO, LCI, NTES, OMER, GIII, WDAY, ZS, RVNC, VRAY
HIGHER: Lannett (LCI), up…
HIGHER: Lannett (LCI), up 9% after announcing results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the HEC Group of companies. The study met all primary endpoints... GoPro (GPRO), up 5% after reporting record sales from the Black Friday and Cyber Monday shopping period... NetEase (NTES), up 2% after Goldman Sachs analyst Bill Liu upgraded shares to Buy from Neutral with a price target of $368, up from $300... Omeros (OMER), up 9% after announcing data from its clinical trial of the company's investigational complement inhibitor narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. DOWN AFTER EARNINGS: G-III Apparel (GIII), down 8%... Workday (WDAY), down 4%... Zscaler (ZS), down 5%. ALSO LOWER: Revance (RVNC), down 17% after its 6.5M share spot secondary offering priced at $17.00 per share... ViewRay (VRAY), down 2% after its upsized 41.55M share secondary offering priced at $3.13 per share.